Loading...
XNAS
AMPH
Market cap838mUSD
Jul 09, Last price  
19.02USD
1D
0.74%
1Q
-6.63%
Jan 2017
3.26%
IPO
90.01%
Name

Amphastar Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:AMPH chart
P/E
8.55
P/S
1.16
EPS
2.22
Div Yield, %
Shrs. gr., 5y
-0.37%
Rev. gr., 5y
15.53%
Revenues
720m
-1.65%
118,356,000204,323,000229,681,000210,461,000251,519,000255,165,000240,175,000294,666,000322,357,000349,846,000437,768,000498,987,000644,395,000731,967,000719,887,000
Net income
98m
-38.51%
7,752,00018,094,00011,862,000-10,699,000-2,787,00010,532,0004,508,000-5,738,00048,939,0001,403,00062,116,00091,386,000137,545,000159,519,00098,094,000
CFO
156m
-26.84%
19,096,000-1,650,00031,042,00021,052,00010,681,00038,560,00039,209,00038,191,00041,762,00057,266,00097,994,00089,181,000183,503,000213,386,000156,115,000
Dividend
Jun 11, 20100.3 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.
IPO date
Jun 25, 2014
Employees
1,615
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT